Drug Trial Radar · NCT04505098
A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
39,600
Actual
Start
Aug 7, 2020
Primary completion
Dec 15, 2022
Study completion Dec 15, 2022
Sponsor
- Lead sponsor
- Kaiser PermanenteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Amarin Corporation
- First posted
- Aug 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MITIGATE is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial. The MITIGATE Study has been designed to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), also known as Vascepa®, compared to usual standard of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory infection (URI)-related (i.e., COVID-19, influenza, and other known viral respiratory pathogens) morbidity and mortality in a high-risk cohort of adults with established atherosclerotic cardiovascular disease (ASCVD).
Conditions
- Covid19
- Atherosclerosis
- Cardiovascular Diseases
- Upper Respiratory Tract Infections
Interventions
Icosapent ethylDrug
2 g by mouth twice daily for at least 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of confirmed viral URIsTime frame: 0-12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Division of Research
Oakland, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.